Suggested remit: To appraise the clinical and cost effectiveness of ruxolitinib within its marketing authorisation for treating non-segmental vitiligo in people 12 years and over.
Status
|
In progress
|
Technology type
|
Medicine
|
Decision
|
Selected
|
Process |
STA Standard
|
ID number |
3998
|
Project Team
Email enquiries
External Assessment Group |
Peninsula Technology Assessment Group (PenTAG), University of Exeter |
Stakeholders
Companies sponsors |
Incyte (ruxolitinib) |
Others |
Department of Health and Social Care |
|
NHS England |
Patient carer groups |
Gene People |
|
Vitiligo Society |
|
Vitiligo Support UK |
Professional groups |
British Association of Dermatologists |
|
British Dermatological Nursing Group |
|
Royal College of Physicians |
Comparator companies |
None |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
British National Formulary |
|
Department of Health, Social Services and Public Safety for Northern Ireland |
|
Healthcare Improvement Scotland |
|
Medicines and Healthcare products Regulatory Agency |
|
Scottish Medicines Consortium |
|
Welsh Government |
|
Welsh Health Specialised Services Committee |
Relevant research groups |
National Institute for Health Research |
Date
|
Update
|
31 January 2024 - 21 February 2024
|
Draft guidance |
07 February 2024
|
We issued draft guidance for consultation on 24 January 2024 and the company, Incyte Corporation, has asked to provide additional evidence to address the committee’s requests as part of their response to the consultation.
To allow time for the additional evidence to be submitted by the company and to be critiqued by the External Academic Group, this will no longer be discussed at the committee meeting on 6 March 2024. The second committee meeting discussion will be rearranged, and we will update all stakeholders with the new date in due course.
|
11 January 2024
|
Committee meeting |
08 June 2023
|
Invitation to participate |
11 May 2023 (14:00)
|
Scoping workshop |
16 March 2023 - 17 April 2023
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 3998 |
17 June 2022
|
Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-April 2023. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
24 November 2021
|
In progress. DHSC referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual